ИСТИНА |
Войти в систему Регистрация |
|
ИСТИНА ЦЭМИ РАН |
||
Development of novel drugs requires application of cutting edge research techniques. NMR (Nuclear Magnetic Resonance) spectroscopy provides a wide variety of methods to monitor and characterize target-ligand interactions. Obtained information on ligand affinity, binding mode and kinetic can be used to drive optimization of the lead compound. NMR-screening guided fragment-based drug design has proven its efficiency for the development of bioactive compounds and is widely used in pharmaceutical industry. Two FDA-approved drugs have been designed using these techniques: venetoclax is implemented to treat chronic lymphocytic leukemia and vemurafenib is prescribed to the patients with BRAF-positive melanoma. Several compounds are in late phases of clinical trials. This report delivers review of modern NMR spectroscopy methods for drug design.